TRD205
Phase 2Small molecule
TRD205 is one of 16 small molecule programs targeting Hallux valgus. It is currently in Phase 2.
3
Indications
4
Total Trials
3
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Neuralgia
#DrugCompanyPhaseTrials
1Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cymbalta
Jazz PharmaceuticalsApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Marcaine
IInnocoll
Approved
Fycompa
CCatalyst Biosciences
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
TRD205
BBeijing Tide Pharmaceutical Co., Ltd
Phase 2
Cymbalta
Jazz PharmaceuticalsPreclinical
Journavx
Vertex PharmaceuticalsPreclinical
DS-5565
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hallux valgus1 trial
Postoperative Analgesia After Unilateral Hip Arthroplasty1 trial
Neuralgia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TRD205. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details